NasdaqCM - Nasdaq Real Time Price USD

Cerevel Therapeutics Holdings, Inc. (CERE)

42.47

+0.40

(+0.95%)

At close: 4:00 PM EDT

42.47

0.00

(0.00%)

After hours: 4:20 PM EDT

Heard on the Street: AbbVie’s Bet on a Neuroscience Drug Maker Just Got Better

AbbVie’s acquisition of neuroscience biotech Cerevel Therapeutics hasn’t closed yet. Notably, when AbbVie announced the $8.7 billion acquisition of Cerevel back in December, the main focus of the deal was the experimental schizophrenia drug Emraclidine, part of a new class of medications that target the muscarinic receptor. Late last year, Bristol Myers Squibb also announced its entry into the field, buying Karuna Therapeutics for $14 billion. The Food and Drug Administration is reviewing Karuna’s drug for the treatment of schizophrenia.

The Wall Street Journal 8 days ago

CERE
+0.95%
ABBV
Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease

Tavapadon met the primary endpoint in the pivotal Phase 3 TEMPO-3 adjunctive trial, demonstrating a statistically significant increase in total “on” time without troublesome dyskinesia compared with placebo over 27 weeks Results demonstrate tavapadon’s potential to provide the right balance of motor control, safety and tolerability for people living with Parkinson’s disease Additional data from the trial will be presented at a future medical meeting; results from the tavapadon Phase 3 monotherap

GlobeNewswire 8 days ago

CERE
+0.95%
AbbVie acquiring Cerevel Therapeutics in $8.7B deal

AbbVie (ABBV) announced it is acquiring neuroscience drug developer Cerevel Therapeutics (CERE) for $45.00 per share, putting the deal value at about $8.7 billion. AbbVie Chairman and CEO Richard Gonzalez said in the announcement that the combined portfolios will present a "significant growth opportunity well into the next decade." The deal comes about a week after AbbVie announced it was acquiring cancer drugmaker ImmunoGen (IMGN) for just over $10 billion. Yahoo Finance Healthcare Reporter Anjalee Khemlani breaks down the deal.  For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.

Yahoo Finance Video 4 months ago

ABBV

IMGN

CERE
+0.95%
AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline

AbbVie Inc. (NYSE: ABBV) and Cerevel Therapeutics (NASDAQ: CERE) today announced a definitive agreement under which AbbVie will acquire Cerevel Therapeutics and its robust neuroscience pipeline of multiple clinical-stage and preclinical candidates with potential across several diseases including schizophrenia, Parkinson's disease (PD), and mood disorders. The acquisition complements AbbVie's neuroscience portfolio, adding a wide range of potentially best-in-class assets that may transform standa

PR Newswire 4 months ago

ABBV

CERE
+0.95%
Cerevel Therapeutics to Host Investor Webcast on Tavapadon in Parkinson’s Disease

Event will focus on tavapadon, a D1/D5 partial agonist in Phase 3 development for the treatment of Parkinson’s disease Live webcast scheduled for Monday, December 11 from 10:00 to 11:30 a.m. ET CAMBRIDGE, Mass., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced it will host a tavapadon investor webcast on Monday, December 11, from 10:00 to 11:30 a.m. ET. Cerevel will lead a

GlobeNewswire 4 months ago

CERE
+0.95%
Cerevel Therapeutics to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that members of the management team will participate in two upcoming investor conferences during the month of November. President and chief executive officer Ron Renaud will also participate in fireside chats at both conferences. Event:Jefferies London Healthcare Conference Date:November 14, 2023Time:

GlobeNewswire 5 months ago

CERE
+0.95%
Cerevel Therapeutics Holdings Inc (CERE) Reports Q3 2023 Financial Results

Company Raises $499 Million from Public Offering, Expects to Support Operations into 2026

GuruFocus.com 5 months ago

CERE
+0.95%
Cerevel Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates

Raised $499 million of net proceeds from public offering of common stock, expected to support operations into 2026 2024 data readout timelines for emraclidine, darigabat, and tavapadon remain on track Tavapadon investor webcast scheduled for December 11, 2023 Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today reported fina

GlobeNewswire 5 months ago

CERE
+0.95%
Cerevel Therapeutics to Report Third Quarter 2023 Financial Results and Business Updates on Wednesday, November 1, 2023

CAMBRIDGE, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report third quarter 2023 financial results and business updates on Wednesday, November 1, 2023, before the U.S. financial markets open. Management will host a conference call to discuss third quarter financial results and business updates on Wednesday, November 1 at 8:00 a.m. ET. To access th

GlobeNewswire 6 months ago

CERE
+0.95%
Cerevel Therapeutics Announces Pricing of $450 Million Public Offering of Common Stock

CAMBRIDGE, Mass., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics Holdings, Inc. (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today the pricing of its previously announced underwritten public offering of 19,728,189 shares of its common stock at a public offering price of $22.81 per share, or approximately $450 million of shares of its common stock. In addition, Cerevel granted the underwriters a 30-day option to pur

GlobeNewswire 6 months ago

CERE
+0.95%
Cerevel Therapeutics Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics Holdings, Inc. (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today that it has commenced an underwritten public offering of $400.0 million of shares of its common stock. In connection with this offering, Cerevel expects to grant the underwriters a 30-day option to purchase up to an additional $60.0 million of shares of its common stock at the public of

GlobeNewswire 6 months ago

CERE
+0.95%
Cerevel Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference

CAMBRIDGE, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that members of the management team will participate in the Morgan Stanley 21st Annual Global Healthcare Conference on Tuesday, September 12, 2023. President and chief executive officer Ron Renaud will participate in a fireside chat at 9:30 AM ET. The live webcast of the fireside chat can be accessed on th

GlobeNewswire 7 months ago

CERE
+0.95%
Insiders Buy the Dip in These 2 Beaten-Down Stocks, Analysts Say They Could Be Ready to Bounce Back — Here’s Why You Should Pay Attention

Whether you’re a seasoned trader or a novice, the oldest piece of advice in economics still holds true: buy low and sell high. The challenge lies in determining the right time to purchase stocks that are undervalued or to sell those that are overpriced. There are plenty of signs to crack that code, but one of the clearest is the insiders’ trading patterns. The insiders are corporate officers, companies’ higher-ups, whose positions put them ‘in the know.’ Therefore, monitoring their trades, espec

TipRanks 8 months ago

ZBRA

CERE
+0.95%
Cerevel Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates

Three new executives added to leadership team: Ron Renaud, Susan Altschuller, Paul Burgess Emraclidine EMPOWER data now expected second half 2024 Darigabat ADAPT trial in panic disorder initiated Cash, cash equivalents, and marketable securities of $825.1 million as of June 30, 2023, expected to support a data-rich 2024 and fund operations into 2025 Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated

GlobeNewswire 8 months ago

CERE
+0.95%
Cerevel Therapeutics to Report Second Quarter 2023 Financial Results and Business Updates on Wednesday, August 2, 2023

CAMBRIDGE, Mass., July 05, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report second quarter 2023 financial results and business updates on Wednesday, August 2, 2023, before the U.S. financial markets open. Management will host a conference call to discuss second quarter financial results and business updates on Wednesday, August 2 at 8:00 a.m. ET. To access the

GlobeNewswire 9 months ago

CERE
+0.95%
Cerevel Therapeutics Appoints Paul Burgess as Chief Business Development and Strategic Operations Officer

Mr. Burgess will be responsible for leading Cerevel’s business development and quality teams Mr. Burgess to join Cerevel effective June 20, 2023 CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced the appointment of Paul Burgess as chief business development and strategic operations officer, effective June 20, 2023. “I am so pleased to welcome Paul to

GlobeNewswire 10 months ago

CERE
+0.95%
Cerevel Therapeutics Appoints Susan Altschuller, Ph.D. as Chief Financial Officer

Susan Altschuller, Ph.D. brings financial management, investor relations, and business planning experience from leading pharmaceutical and biotechnology companies to Cerevel Dr. Altschuller to become CFO effective May 15, 2023 CAMBRIDGE, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced the appointment of Susan Altschuller, Ph.D. as chief financial officer (CFO)

GlobeNewswire 11 months ago

CERE
+0.95%
Cerevel Therapeutics Appoints Ron Renaud as President and Chief Executive Officer and Reports First Quarter 2023 Financial Results

Ron Renaud to succeed Tony Coles, M.D. as CEO, effective June 12, 2023; Dr. Coles will continue as chairperson of the board Mr. Renaud brings more than 25 years of biotechnology leadership to Cerevel, including two prior CEO roles and strong financial and operational experience Emraclidine Phase 2 schizophrenia data readout on track for 1H 2024 Darigabat Phase 2 epilepsy data readout expected mid-year 2024; panic disorder Phase 2 trial expected to initiate in Q2 2023 Cash, cash equivalents, and

GlobeNewswire 11 months ago

CERE
+0.95%

Performance Overview

Return	CERE	S&P 500
YTD	+0.17%	+6.92%
1-Year	+51.73%	+25.26%
3-Year	+182.76%	+22.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Cerevel Therapeutics Holdings, Inc. (CERE)

Heard on the Street: AbbVie’s Bet on a Neuroscience Drug Maker Just Got Better

Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease

AbbVie acquiring Cerevel Therapeutics in $8.7B deal

AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline

Cerevel Therapeutics to Host Investor Webcast on Tavapadon in Parkinson’s Disease

Cerevel Therapeutics to Present at Upcoming Investor Conferences

Cerevel Therapeutics Holdings Inc (CERE) Reports Q3 2023 Financial Results

Cerevel Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates

Cerevel Therapeutics to Report Third Quarter 2023 Financial Results and Business Updates on Wednesday, November 1, 2023

Cerevel Therapeutics Announces Pricing of $450 Million Public Offering of Common Stock

Cerevel Therapeutics Announces Proposed Public Offering of Common Stock

Cerevel Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference

Insiders Buy the Dip in These 2 Beaten-Down Stocks, Analysts Say They Could Be Ready to Bounce Back — Here’s Why You Should Pay Attention

Cerevel Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates

Cerevel Therapeutics to Report Second Quarter 2023 Financial Results and Business Updates on Wednesday, August 2, 2023

Cerevel Therapeutics Appoints Paul Burgess as Chief Business Development and Strategic Operations Officer

Cerevel Therapeutics Appoints Susan Altschuller, Ph.D. as Chief Financial Officer

Cerevel Therapeutics Appoints Ron Renaud as President and Chief Executive Officer and Reports First Quarter 2023 Financial Results

Performance Overview